Mianserin and convulsive seizures.
1 Forty patients have been reported to the Committee on Safety of Medicines (CSM) because of convulsions occurring during treatment with mianserin, suggesting that this drug is more epileptogenic than tricyclic antidepressants. 2 Details concerning 83% of these cases were obtained in a questionnaire study carried out in collaboration with the CSM and compared with those of a control group. 3 Ratings of the relationship between drug and effect carried out by neurologists and J.G.E. showed considerable variations and confidence of a causal connection in only a minority of patients. 4 As the CSM data do not allow for a reliable assessment of the relative epileptogenic effects of antidepressants, a comparison has been made between unpublished work on seizures occurring during treatment with imipramine and amitriptyline and published research on mianserin. This suggests that mianserin is no more epileptogenic than tricyclic antidepressants. 5 Factors that might predispose to seizures include relevant family and past medical history, starting treatment, a change in dose, benzodiazepine withdrawal and concomitant treatment with other drugs that have epileptogenic properties.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D002648:Child; D003984:Dibenzazepines / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D012640:Seizures / Q000139:chemically induced* / Q000235:genetics; D012737:Sex Factors; D013997:Time Factors
D003984:Dibenzazepines; D008803:Mianserin